Physician profile
Aiman M Abboud
NPI 1063511970
$4,459.71
in general payments reported to CMS, 2019-2025
24 companies · $936 in 2025
The $936 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $157 · 2021: $339 · 2022: $989 · 2023: $812 · 2024: $881 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,530 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,530.20 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $984.51 | 2023-2025 | Gemtesa, Myfembree |
| Astellas Pharma US INC | $543.14 | 2019-2025 | Veozah, Myrbetriq |
| Myovant Sciences INC. | $503.44 | 2021-2022 | |
| Abbvie INC. | $318.84 | 2019-2025 | Liletta |
| Exeltis, USA INC. | $318.15 | 2019-2025 | Slynd |
| Coopersurgical, INC. | $303.51 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Medtronic, INC. | $252.64 | 2024-2025 | Ligasure, Truclear |
| Therapeuticsmd, INC. | $232.86 | 2019-2022 | |
| Urovant Sciences INC | $210.27 | 2021-2022 | |
| Shield Therapeutics INC | $180.90 | 2024-2025 | |
| Pfizer INC. | $175.84 | 2022-2024 | |
| Biogen, INC. | $90.45 | 2025 | Zurzuvae |
| Allergan, INC. | $52.85 | 2019-2021 | |
| Merz North America, INC. | $46.41 | 2019 | |
| Amag Pharmaceuticals, INC. | $41.98 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $38.93 | 2024 | Ycanth |
| Mission Pharmacal Company | $28.04 | 2019 | |
| Avion Pharmaceuticals | $27.38 | 2019-2020 | |
| Boston Scientific Corporation | $23.53 | 2019 | |
| Quidel Corporation | $20.01 | 2020 | |
| Hologic Sales and Service, LLC | $18.21 | 2021 | |
| Roche Diagnostics Corporation | $17.89 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.60 | 2023 | Xifaxan |
| Minerva Surgical, INC | $13.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aiman Abboud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.